Valuation: Hwail Pharmaceutical Co.,Ltd.

Market Cap 92.09B 123,104B 83.45B 77.19B 69.64B 131B 8,683B 136B 927B 368B 4,638B 346B 338B 14,723B P/E 2015
16x
P/E 2016 17.2x
Enterprise Value 97.14B 129,849B 88.02B 81.42B 73.46B 138B 9,159B 143B 978B 388B 4,892B 365B 357B 15,530B EV / Sales 2015
1.01x
EV / Sales 2016 1.03x
Free-Float
49.37%
Yield 2015 *
-
Yield 2016 -
09-15 An undisclosed buyer agreed to acquire 8.19% stake in Hwail Pharmaceutical Co.,Ltd. from Kumho HT, Inc. for KRW 22.1 billion. CI
09-15 Osung Advanced Materials Co., Ltd. acquired an additional 19.66% stake in Hwail Pharmaceutical Co.,Ltd. for KRW 52.9 billion. CI
09-14 Pharma & Bio New Technology Fund entered into an agreement to acquire 27.84% stake in Hwail Pharmaceutical Co.,Ltd. from Osung Advanced Materials Co., Ltd. and Kumho HT, Inc. for KRW 75 billion. CI
02-11 Hwail Pharmaceutical to Retire KRW4.98 Billion Worth of Treasury Stock MT
25-06-30 Osung Advanced Materials Co., Ltd. acquired an additional 17.75% stake in Hwail Pharmaceutical Co.,Ltd. from Eco Volt Co.,Ltd. and Kumho HT, Inc.. CI
25-06-10 Osung Advanced Materials Co., Ltd. entered into agreement to acquire an additional 17.75% stake in Hwail Pharmaceutical Co.,Ltd. from Eco Volt Co.,Ltd. and Kumho HT, Inc. for KRW 26.5 billion. CI
24-10-22 Hwail Pharmaceutical Co.,Ltd. announced that it has received KRW 7.999999334 billion in funding from Nexkonics Inc. CI
24-10-14 Hwail Pharmaceutical Co.,Ltd. announced that it expects to receive KRW 7.999999334 billion in funding from Nexkonics Inc. and another investor CI
24-04-17 Hwail Pharmaceutical Co.,Ltd. announced that it has received KRW 19.0999977 billion in funding from Osung Advanced Materials Co., Ltd., Kumho HT, Inc., CrystalGenomics Invites Co., LTD. CI
24-03-26 PanGen Biotech Inc. announced that it has received KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd. CI
24-03-17 PanGen Biotech Inc. announced that it expects to receive KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd. CI
24-02-21 Tranche Update on Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on August 21, 2023. CI
24-02-21 Tranche Update on Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on August 21, 2023. CI
1 day+0.93%
1 week+1.11%
Current month-2.68%
1 month-10.07%
3 months-36.48%
6 months-35.27%
Current year-52.32%
1 week 5,010
Extreme 5010
5,550
1 month 5,010
Extreme 5010
6,380
Current year 5,010
Extreme 5010
11,810
1 year 5,010
Extreme 5010
12,500
3 years 5,010
Extreme 5010
22,800
5 years 5,010
Extreme 5010
37,550
10 years 5,010
Extreme 5010
59,333.33
Manager TitleAgeSince
Chief Executive Officer 38 2026-03-29
Chief Executive Officer 67 -
Chief Executive Officer 66 -
Director TitleAgeSince
Chairman 66 -
Director/Board Member 67 -
Director/Board Member 51 2024-03-18
Date Insider Type Main position Quantity % Market Cap. Importance
8/18/25 Others

Responsable ventes & marketing

16,233 0.0196%
6/11/25 Others 16,233 0.0196%
Change 5-day change 1-year change 3-year change Capi.($)
+0.93%+1.11% - - 34.3M
Average +0.93%
Weighted average by Cap. +0.93%

Financials

2015 2016
Net sales 106B 141,871B 96.18B 88.96B 80.26B 151B 10,007B 157B 1,069B 424B 5,345B 398B 390B 16,968B 112B 149,075B 101B 93.47B 84.34B 159B 10,515B 165B 1,123B 445B 5,617B 418B 410B 17,829B
Net income 5.45B 7,289B 4.94B 4.57B 4.12B 7.77B 514B 8.05B 54.91B 21.77B 275B 20.46B 20.03B 872B 6.38B 8,531B 5.78B 5.35B 4.83B 9.09B 602B 9.42B 64.26B 25.48B 321B 23.95B 23.44B 1,020B
Net Debt 20.17B 26,956B 18.27B 16.9B 15.25B 28.74B 1,901B 29.75B 203B 80.51B 1,016B 75.67B 74.07B 3,224B 5.05B 6,744B 4.57B 4.23B 3.82B 7.19B 476B 7.44B 50.8B 20.14B 254B 18.93B 18.53B 807B
Logo Hwail Pharmaceutical Co.,Ltd.
Hwail Pharm Co Ltd is a Korea-based company mainly engaged in the manufacture and distribution of pharmaceutical raw materials. The Company mainly produces aceclofenac, lornoxicam, triflusal, dicloalphenazone, gallamine triethyl iodide, acemetacin, levosulpiride, alibendol, erdostein, talniflumate, topiramate, phloroglucin, oxatomide and others used as expectorants, cough remedies, antispasmodics, analgesics, anti-inflammatories and others under the brand name EDST, TRPR, LVSP, ACCL and others. The Company also provides finished formulations, including injection products such as ceftazidime, cefoperazone, cefotaxime, cefaclor, cefatrizine, cefroxadine and others.
Employees
130
Date Price Change Volume
26-11-13 ₩5,450.00 +0.93% 2,688
26-11-12 ₩5,400.00 -0.37% 1,912
26-11-11 ₩5,420.00 +3.63% 4,235
26-11-10 ₩5,230.00 -0.76% 64,924
26-11-09 ₩5,270.00 -2.23% 7,370
  1. Stock Market
  2. Stocks
  3. A061250 Stock